Effects of intravitreal injection of bevacizumab on nitric oxide levels

Basit Öğe Kaydı
dc.authoridyilmaz, şakir necat/0000-0003-1759-3052
dc.authoridYilmaz, Nejat/0000-0003-0637-3687
dc.authoridAYAZ, LOKMAN/0000-0002-2876-055X
dc.authorwosidOzcan Metin, Tuba/HKF-6974-2023
dc.authorwosidyilmaz, şakir necat/AAA-5270-2022
dc.authorwosidYilmaz, Nejat/JMB-6519-2023
dc.authorwosidAYAZ, LOKMAN/K-6716-2013
dc.contributor.authorDinc, E.
dc.contributor.authorYildirim, O.
dc.contributor.authorAyaz, L.
dc.contributor.authorOzcan, T.
dc.contributor.authorYilmaz, S. N.
dc.date.accessioned2024-06-12T11:18:48Z
dc.date.available2024-06-12T11:18:48Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose This study aimed to determine the possible effects of single-dose intravitreal bevacizumab on nitric oxide (NO) levels in serum and remote organs and to reveal one of the possible mechanisms in the pathophysiology of hypertension. Methods Thirty-eight adult New Zealand albino rabbits were divided into a control group (no injection was performed, killed on day 28 of the study), group 1 (killed on day 1 of the study), group 2 (killed on day 7 of the study), group 3 (killed on day 14 of the study), and group 4 (killed on day 28 of the study). The right eyes of the animals in groups 1-4 received an intravitreal single injection of 1.25mg (0.05ml) bevacizumab (Avastin), and their brain, heart, liver, kidney, and blood samples were collected. NO levels were evaluated in the serum and organ homogenates. Kidney tissues were assessed by electron microscopy. Results Serum, brain, kidney, and liver NO levels significantly decreased in groups 2, 3, and 4 as compared with the control group (P<0.05). In addition, heart NO levels significantly decreased in groups 3 and 4 compared with the control group (P<0.05). There were no electron microscopic changes in the kidneys of either group. Conclusions This study demonstrated that single intravitreal injection of bevacizumab decreased NO levels in serum, brain, heart, liver, and kidneys. In addition, there were no electron microscopic changes in the kidneys.en_US
dc.description.sponsorshipMersin University Scientific Research Fund [BAP-TF CTB (ED) 2011-3 TU]en_US
dc.description.sponsorshipThis study was supported by Mersin University Scientific Research Fund (Grant No: BAP-TF CTB (ED) 2011-3 TU).en_US
dc.identifier.doi10.1038/eye.2014.297
dc.identifier.endpage442en_US
dc.identifier.issn0950-222X
dc.identifier.issn1476-5454
dc.identifier.issue3en_US
dc.identifier.pmid25523201en_US
dc.identifier.scopus2-s2.0-84924854178en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage436en_US
dc.identifier.urihttps://doi.org/10.1038/eye.2014.297
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24969
dc.identifier.volume29en_US
dc.identifier.wosWOS:000350880300020en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNature Publishing Groupen_US
dc.relation.ispartofEyeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectChoroidal Neovascularization Secondaryen_US
dc.subjectMacular Degenerationen_US
dc.subjectAvastin Therapyen_US
dc.subjectTyrosine Kinaseen_US
dc.subjectVegfen_US
dc.subjectExpressionen_US
dc.subjectReceptoren_US
dc.subjectCanceren_US
dc.subjectPermeabilityen_US
dc.titleEffects of intravitreal injection of bevacizumab on nitric oxide levelsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu